2015
Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis
Cortesi P, Mantovani L, Ciaccio A, Rota M, Mazzarelli C, Cesana G, Strazzabosco M, Belli L. Cost-Effectiveness of New Direct-Acting Antivirals to Prevent Post-Liver Transplant Recurrent Hepatitis. American Journal Of Transplantation 2015, 15: 1817-1826. PMID: 26086300, PMCID: PMC4946849, DOI: 10.1111/ajt.13320.Peer-Reviewed Original ResearchRecipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort
Belli LS, Romagnoli R, Nardi A, Marianelli T, Donato F, Corradini SG, Iemmolo RM, Morelli C, Pasulo L, Rendina M, De Martin E, Ponziani FR, Volpes R, Strazzabosco M, Angelico M, Investigators L. Recipient female gender is a risk factor for graft loss after liver transplantation for chronic hepatitis C: Evidence from the prospective Liver Match cohort. Digestive And Liver Disease 2015, 47: 689-694. PMID: 26055490, DOI: 10.1016/j.dld.2015.04.006.Peer-Reviewed Original ResearchConceptsRecipient female genderGraft lossFemale genderLiver transplantationRisk factorsEnd-stage liver disease (MELD) scoreFive-year graft survivalStage liver disease scoreOutcome of HCVSevere HCV recurrenceChronic hepatitis CHCV-positive patientsLiver Disease scoreHepatitis C virusHCV recurrenceGraft outcomeGraft survivalHepatitis CPortal thrombosisTransplant recipientsLiver graftsIndependent determinantsRetrospective studyC virusMatch cohort
2014
Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options
Cortesi PA, Ciaccio A, Rota M, Lim JK, De Salvia S, Okolicsanyi S, Vinci M, Belli LS, Mantovani LG, Strazzabosco M. Management of treatment‐naïve chronic hepatitis C genotype 1 patients: a cost‐effectiveness analysis of treatment options. Journal Of Viral Hepatitis 2014, 22: 175-183. PMID: 25040391, PMCID: PMC4519006, DOI: 10.1111/jvh.12278.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioEnd-stage liver diseaseCost-effectiveness analysisF3-F4Liver diseaseChronic hepatitis C genotype 1 patientsHepatitis C genotype 1 patientsItalian National Health System perspectiveNational Health System perspectiveResponse-guided therapyGenotype 1 patientsMETAVIR fibrosis stageHealth system perspectiveQuality-adjusted life yearsPatient selection strategiesCost-effectiveness ratioG1 patientsNaive patientsTriple therapyOnly patientsAdvanced fibrosisFuture regimensMore regimensTreatment optionsFibrosis stage